Hazlett, Burt & Watson’s AstraZeneca AZN Stock Holding History

Hazlett, Burt & Watson’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$212K	Buy	1,079 +129	+14%	+$24.9K	0.07%	240
2025 Q4	$175K	Hold	950	–	–	0.06%	268
2025 Q3	$146K	Hold	950	–	–	0.05%	271
2025 Q2	$134K	Sell	950 -12	-1%	-$1.68K	0.05%	243
2025 Q1	$142K	Hold	962	–	–	0.06%	233
2024 Q4	$126K	Buy	962 +48	+5%	+$6.72K	0.06%	252
2024 Q3	$143K	Buy	914 +58	+7%	+$9.36K	0.07%	242
2024 Q2	$133K	Buy	856 +232	+37%	+$34.9K	0.07%	234
2024 Q1	$86K	Hold	624	–	–	0.05%	264
2023 Q4	$82K	Sell	624 -40	-6%	-$5.2K	0.06%	244
2023 Q3	$91K	Buy	664 +301	+83%	+$41.1K	0.07%	226
2023 Q2	$52K	Buy	363 +6	+2%	+$883	0.04%	292
2023 Q1	$50K	Hold	357	–	–	0.04%	276
2022 Q4	$48K	Buy	357 +100	+39%	+$12.5K	0.04%	274
2022 Q3	$28K	Buy	257 +145	+129%	+$18.4K	0.03%	331
2022 Q2	$15K	Hold	112	–	–	0.01%	408
2022 Q1	$15K	Buy	+112	New	+$13.4K	0.01%	421

Other funds holding AZN

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VAM

Vanguard Asset Management London, Ec4n 8af $117B AUM

Hazlett, Burt & Watson's AZN Position: Q1 2026 in Review

Hazlett, Burt & Watson increased its AstraZeneca (AZN) stake by 14% in Q1 2026, buying an estimated $24.9K and bringing the position to 1,079 shares worth $212K. The position accounts for 0.07% of the portfolio, ranked #240.

Hazlett, Burt & Watson first reported a position in AZN in Q1 2022 and has held it in 17 quarters since. 1,378 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

Hazlett, Burt & Watson held 1,079 shares of AstraZeneca worth $212K as of Q1 2026.
Hazlett, Burt & Watson bought 129 AstraZeneca shares in Q1 2026, an estimated $24.9K.
AstraZeneca made up 0.07% of Hazlett, Burt & Watson's portfolio in Q1 2026, its #240 holding.
Hazlett, Burt & Watson first reported a position in AstraZeneca in Q1 2022 and has held it in 17 quarters since.
1,378 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Hazlett, Burt & Watson's 13F filing for Q1 2026, filed 14 May 2026.